Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.81 |
| ▸ | NPC1 | O15118 | 6/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | BCL3 | P20749 | 3/20 | 0.59 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30560609 | 1.00 | RAB9A (0.81) | RAB9ANPC1SMN1; SMN2ALDH1A1BCL3 | |
| SCHEMBL17554123 | 0.92 | NPC1 (0.68) | RAB9ANPC1SMN1; SMN2ALDH1A1BCL3 | |
| SCHEMBL2352332 | 0.90 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL17554094 | 0.89 | RAB9A (0.71) | RAB9ANPC1SMN1; SMN2ALDH1A1BCL3 | |
| SCHEMBL17554161 | 0.88 | RAB9A (0.71) | RAB9ANPC1SMN1; SMN2ALDH1A1BCL3 | |
| SCHEMBL5750887 | 0.85 | BACE1 (0.63) | RAB9ANPC1SMN1; SMN2ALDH1A1MT-CO2 | |
| SCHEMBL29849764 | 0.85 | BCL3 (0.62) | RAB9ANPC1SMN1; SMN2ALDH1A1BCL3 | |
| SCHEMBL16431496 | 0.85 | BCL3 (0.62) | RAB9ANPC1SMN1; SMN2ALDH1A1BCL3 | |
| SCHEMBL17554032 | 0.84 | RAB9A (0.64) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL17554153 | 0.84 | NPC1 (0.57) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3628374-B1 | BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2023-08-30 | — | — | EP | disclosed |
| EP-3628374-B1 | BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2023-08-30 | — | — | EP | disclosed |
| EP-3628374-A2 | BCL-3 INHIBITORS | University College Cardiff Consultants Limited (GB) | 2020-04-01 | — | — | EP | disclosed |
| EP-3628374-A2 | BCL-3 INHIBITORS | University College Cardiff Consultants Limited (GB) | 2020-04-01 | — | — | EP | disclosed |
| US-20190248756-A1 | BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2019-08-15 | — | — | US | disclosed |
| US-20190248756-A1 | BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2019-08-15 | — | — | US | disclosed |
| US-10273218-B2 | BCL-3 inhibitors | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2019-04-30 | — | — | US | disclosed |
| US-10273218-B2 | BCL-3 inhibitors | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2019-04-30 | — | — | US | disclosed |
| US-20170267653-A1 | BCL-3 INHIBITORS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2017-09-21 | — | — | US | disclosed |
| US-20170267653-A1 | BCL-3 INHIBITORS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2017-09-21 | — | — | US | disclosed |
| EP-3174602-A2 | BCL-3 INHIBITORS | University College Cardiff Consultants Limited (GB) | 2017-06-07 | — | — | EP | disclosed |
| WO-2016016728-A2 | BCL-3 INHIBITORS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2016-02-04 | — | — | WO | disclosed |
| EP-1558260-A4 | QUINAZOLINONE COMPOUNDS AS CALCILYTICS | NPS PHARMA INC (US) | 2006-10-25 | — | — | EP | disclosed |
| US-20060052345-A1 | Quinazolinone compounds as calcilytics | NPS PHARMACEUTICALS, INC. (US) | 2006-03-09 | — | — | US | disclosed |
| EP-1558260-A2 | QUINAZOLINONE COMPOUNDS AS CALCILYTICS | NPS PHARMACEUTICALS, INC. (US) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004041755-A2 | QUINAZOLINONE COMPOUNDS AS CALCILYTICS | NPS PHARMACEUTICALS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248756-A1 | BCL-3 INHIBITORS | BCL3, BCL2, BCL2L13 | RAB9A 922/4885NPC1 3070/4885SMN1; SMN2 4161/4885 |
| US-10273218-B2 | BCL-3 inhibitors | BCL3, BCL2, BCL2L13 | RAB9A 934/4885NPC1 3457/4885SMN1; SMN2 4241/4885 |
| US-20060052345-A1 | Quinazolinone compounds as calcilytics | CALCR, CALCRL, CASR | RAB9A 444/4885NPC1 2093/4885SMN1; SMN2 4811/4885 |
| US-20170267653-A1 | BCL-3 INHIBITORS | BCL3, BCL2, BCL2L13 | RAB9A 934/4885NPC1 3457/4885SMN1; SMN2 4241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.